stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) Return on equity
Indivior Pharmaceuticals Inc.'s return on equity over the twelve months to 30 September 2026 was −337.8%, down 241.5 percentage points from fiscal 2025 (−96.3%). Over the past ten years it has ranged from −401.5% (fiscal 2018) to 183.0% (fiscal 2023); the current reading is higher than 27% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −0.80% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −96.3% | (93.68) |
| FY2024 | −2.65% | (185.63) |
| FY2023 | 183.0% | 224.71 |
| FY2022 | −41.7% | (185.59) |
| FY2021 | 143.9% | 245.58 |
| FY2020 | −101.7% | (199.17) |
| FY2019 | 97.5% | 498.91 |
| FY2018 | −401.5% | (378.17) |
| FY2017 | −23.3% | (11.09) |
| FY2016 | −12.2% | 48.28 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LQDA Liquidia Corporation compare | 131.8% |
| LNTH Lantheus Holdings, Inc. compare | 21.8% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 17.6% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| ALKS Alkermes plc compare | −0.02% |
| HIMS Hims & Hers Health, Inc. compare | −32.0% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −74.7% |
| SUPN Indivior Pharmaceuticals Inc. | −337.8% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −53,107.2% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on SUPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement